Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic peripheral blood stem cell transplantation

T R Spitzer1

  • 1Massachusetts General Hospital, Harvard Medical School, USA.

The Journal of Infusional Chemotherapy
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact.

Bone marrow transplantation·2017
Same author

Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Bone marrow transplantation·2017
Same author

Transfusion practices for bone marrow harvests: a survey analysis from the AABB Bone Marrow Quality Improvement Initiative Working Group.

Bone marrow transplantation·2017
Same author

Preoperative autologous blood donation in healthy bone marrow donors contributes to pre-procedure anemia.

Bone marrow transplantation·2017
Same author

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.

Bone marrow transplantation·2016
Same author

Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation.

Bone marrow transplantation·2015
Same journal

Neoadjuvant chemotherapy with continuous infusion of cisplatin and 5-fluorouracil, with or without leucovorin, for locally advanced nasopharyngeal carcinoma.

The Journal of infusional chemotherapy·1996
Same journal

Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.

The Journal of infusional chemotherapy·1996
Same journal

The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.

The Journal of infusional chemotherapy·1996
Same journal

The French experience with infusional 5-FU in gastric and pancreatic cancer.

The Journal of infusional chemotherapy·1996
Same journal

Drug stability and compatibility in oncology care.

The Journal of infusional chemotherapy·1996
Same journal

Options for venous access in ambulatory care: issues in selection and management.

The Journal of infusional chemotherapy·1996
See all related articles

Mobilized peripheral blood stem cells (PBSC) offer a promising alternative to bone marrow for hematopoietic reconstitution, demonstrating rapid engraftment without increased graft-versus-host disease risk. Further research is needed to confirm long-term donor safety and efficacy in diverse transplant settings.

Area of Science:

  • Hematology
  • Transplantation Immunology
  • Oncology

Background:

  • Mobilized peripheral blood stem cells (PBSC) are increasingly used for hematopoietic reconstitution after myeloablative chemoradiotherapy.
  • PBSC are considered a potentially superior alternative to autologous bone marrow support.
  • Initial concerns included engraftment failure, graft-versus-host disease (GVHD), and donor safety, which have been addressed by recent findings.

Purpose of the Study:

  • To evaluate the efficacy and safety of mobilized PBSC for allogeneic transplantation.
  • To assess engraftment kinetics and GVHD incidence with PBSC.
  • To identify areas for further investigation regarding donor safety and optimal collection strategies.

Main Methods:

  • Review of recent clinical series and reports on mobilized PBSC transplantation.

Related Experiment Videos

  • Analysis of engraftment success, GVHD rates, and donor tolerance to G-CSF.
  • Assessment of CD34+ progenitor cell yields and donor safety profiles.

    • Main Results:

    • Mobilized PBSC transplantation shows rapid and sustained engraftment.
    • No significant increase in moderate to severe acute GVHD observed with unmanipulated PBSC.
    • Excellent donor tolerance to G-CSF and adequate progenitor cell yields reported.

    Conclusions:

    • Mobilized PBSC is an effective option for allogeneic transplantation, offering rapid engraftment and acceptable GVHD rates.
    • Long-term donor safety and lymphohematopoietic reconstitution require further evaluation through prospective trials.
    • Defining optimal collection strategies and exploring PBSC use in unrelated and mismatched donor settings are crucial for widespread adoption.